| Zacks Company Profile for Cumberland Pharmaceuticals Inc. (CPIX : NSDQ) |
|
|
| |
| • Company Description |
| Cumberland Pharmaceuticals, Inc., headquartered in Nashville, Tennessee, is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products for the acute care and gastroenterology markets. The company's lead product candidate, Amelior, which is in phase III clinical trials, is an intravenous formulation of ibuprofen for the treatment of both pain and fever. Its products also comprise Acetadote, an intravenous formulation of N-acetylcysteine for the treatment of acetaminophen poisoning; and Kristalose, a prescription laxative product, which is a crystalline form of lactulose to enhance patient acceptance and compliance. In addition, the company is developing a treatment for fluid buildup in the lungs of cancer patients and an anti-infective for treating fungal infections in immuno-compromised patients.
Number of Employees: 91 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $3.34 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 112,590 shares |
| Shares Outstanding: 14.96 (millions) |
| Market Capitalization: $49.97 (millions) |
| Beta: -0.39 |
| 52 Week High: $7.25 |
| 52 Week Low: $1.04 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-43.00% |
-45.14% |
| 12 Week |
-29.83% |
-40.98% |
| Year To Date |
40.93% |
31.98% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
A. J. Kazimi - Chief Executive Officer;Chairman
John M. Hamm - Vice President; Chief Financial Officer
Gordon R. Bernard - Director
James R. Jones - Director
Caroline R. Young - Director
|
|
Peer Information
Cumberland Pharmaceuticals Inc. (GSAC)
Cumberland Pharmaceuticals Inc. (CASI)
Cumberland Pharmaceuticals Inc. (ALCD.)
Cumberland Pharmaceuticals Inc. (OMNN)
Cumberland Pharmaceuticals Inc. (CGPI.)
Cumberland Pharmaceuticals Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 230770109
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
|
|
Share - Related Items
Shares Outstanding: 14.96
Most Recent Split Date: (:1)
Beta: -0.39
Market Capitalization: $49.97 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: 0.00 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/25 |
|
|
|
| |
